Evidence map›Paper›PMID 39892111›Full record

ArticleVaccine2025

What will introducing and delivering new maternal vaccines cost in Ghana and Mozambique? A prospective analysis.

Ranju Baral, Kwame Amponsa-Achiano, Iracema Barros, Patience Cofie, Patience Dapaah, Jessica A Fleming, Chris Opoku Fofie, Sadaf Khan, Braiton Maculuve, Lauren Newhouse and 6 more

Abstract read
In one paragraph

Article in Vaccine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Ranju BaralCenter for Vaccine Innovation and Access, PATH, Seattle, United States of America. Electronic address: rbaral@path.org.
Kwame Amponsa-AchianoGhana Health Service, Accra, Ghana.
Iracema BarrosPATH, Maputo, Mozambique.
Patience CofiePATH, Accra, Ghana.
Patience DapaahPATH, Accra, Ghana.
Jessica A FlemingCenter for Vaccine Innovation and Access, PATH, Seattle, United States of America.
Chris Opoku FofieGhana Health Service, Accra, Ghana.
Sadaf KhanCenter for Vaccine Innovation and Access, PATH, Seattle, United States of America.
Braiton MaculuveMinistry of Health, Maputo, Mozambique.
Lauren NewhouseCenter for Vaccine Innovation and Access, PATH, Seattle, United States of America.
Leonildo NhampossaMinistry of Health, Maputo, Mozambique.
Rosemond OwusuIndependent consultant, Accra, Ghana.
Melanie PicoloPATH, Maputo, Mozambique.
Diana QuelhasIndependent consultant, Maputo, Mozambique.
Yara Voss De LimaPATH, Maputo, Mozambique.
Clint PecenkaCenter for Vaccine Innovation and Access, PATH, Seattle, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe maternal vaccine landscape is expanding, including the anticipated global rollout of the now approved respiratory syncytial virus maternal vaccine. Integrating maternal immunization (MI) into health systems in low-and middle-income countries (LMICs) will require adaptation to existing immunization delivery platforms and have cost implications. In this study, we project the cost of maternal vaccine introduction and delivery in Ghana and Mozambique to help inform introduction decisions and ensure financial sustainability of future MI interventions.

methodsWe used an activity-based prospective cost projection approach to estimate MI introduction and delivery costs for a five-year period from a health system perspective. Country stakeholders informed the strategies for MI delivery. Interviews with key immunization and maternal health program representatives informed on the anticipated health system adaptation requirements, activities, and resource needs taken into account in the cost projections. Supplementary data from a sample of sub-national health administrative units, vaccine stores, and health facilities also informed the costing analysis. Financial and economic costs are estimated and presented in 2023 USD units.

resultsNew maternal vaccines in both countries are anticipated to be delivered leveraging the existing maternal tetanus vaccine delivery practices. The non-vaccine cost of delivering one dose of maternal vaccine was estimated at $3.42 (financial) and $4.12 (economic) in Ghana, and $1.84 (financial) and $2.21 (economic) in Mozambique. Health worker training, communication and social mobilization, and program planning and coordination constitute the main cost drivers. Cost differences between countries are partly driven by the anticipated baseline coverage and baseline health system capacity gaps. DISCUSSION: Very few studies exist on the costs of delivering maternal vaccine in LMICs. This study begins to fill this gap. These MI cost projections are comparable to other new vaccine introduction costs in similar settings, providing insights for local and global stakeholders seeking to understand costs of MI delivery.

Indexed as

Immunization ProgramsVaccinationVaccinesCosts and Cost AnalysisFemaleGhanaHumansMozambiquePregnancyProspective StudiesVaccinesCostCost of deliveryEconomic costFinancial costMaternal vaccines

Identifiers

PMID39892111
PMCPMC11878280

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.